View More View Less
  • 1 University of Sistan and Baluchestan Department of Biology, Faculty of Sciences Zahedan Iran
  • | 2 Islamic Azad University Department of Biology, Qom Branch Qom Iran
  • | 3 Universiti Putra Malaysia, UPM Department of Biomedical Science, Faculty of Medicine and Health Sciences Serdang Selangor 43400 Malaysia
Open access

Phosphatidylinositol-3-kinase (PI3K) is a group of enzymes involved in cellular growth, proliferation, differentiation, cell motility, intracellular trafficking, and survival that play very important roles in developing breast cancer. PIK3CA is a gene that encodes α catalytic subunit of this enzyme. A common polymorphism of PIK3CA, rs7640662 (C/G), was analyzed, and its association to breast cancer cases was determined. In this study, DNA was extracted from peripheral blood samples of 278 women suffering from breast cancer and 128 healthy women. Tetra-primer amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR) method was performed to genotype rs7640662. P values and ODD ratios were measured using SPSS. P value less than 0.05 and ODD ratios more than 1 were considered as significant. All ODD ratios were less than 1, and P values were more than 0.05 showing that rs7640662 (C/G) and breast cancer are not significantly associated. However, the genotypes observed in the Persian population, as an ancient population living in the Middle East, was significantly different from the genotypes reported by HapMap for Asian populations. As a conclusion, rs7640662 was not associated with the risk of breast cancer in a Persian population; however, it was observed that heterozygote (GC) is the most common genotypes in both case and control samples.

  • American Cancer Society (2013): Cancer Facts and Figures. [Online]. Available: http://globocan.iarc.fr/ . [Accessed: November 5, 2013]

    '', in Cancer Facts and Figures , (2013 ) -.

  • Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling K-H: Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol 740, 584–595 (2014)

    Ling K-H , 'Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer ' (2014 ) 740 Eur J Pharmacol : 584 -595.

    • Search Google Scholar
  • Knight Z, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss W, Williams RL, Shokat KM: A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 125, 733–747 (2006)

    Shokat KM , 'A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling ' (2006 ) 125 Cell : 733 -747.

    • Search Google Scholar
  • Porta C, Paglino C, Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4, 1–11 (2014)

    Mosca A , 'Targeting PI3K/Akt/mTOR signaling in cancer ' (2014 ) 4 Front Oncol : 1 -11.

  • Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC: Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 265, 19704–19711 (1990)

    Schaffhausen B C L , 'Purification and characterization of phosphoinositide 3-kinase from rat liver ' (1990 ) 265 J Biol Chem : 19704 -19711.

    • Search Google Scholar
  • Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ: SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767–778 (1993)

    Lechleider RJ , 'SH2 domains recognize specific phosphopeptide sequences ' (1993 ) 72 Cell : 767 -778.

    • Search Google Scholar
  • Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B: Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity. Mol Cell Biol 14, 5929–5938 (1994)

    Schaffhausen B , 'Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity ' (1994 ) 14 Mol Cell Biol : 5929 -5938.

    • Search Google Scholar
  • Cidado J, Park BH: Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 17, 205–216 (2012)

    Park BH , 'Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy ' (2012 ) 17 J Mammary Gland Biol Neoplasia : 205 -216.

    • Search Google Scholar
  • Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477–1480 (2005)

    Lee SH , 'PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas ' (2005 ) 24 Oncogene : 1477 -1480.

    • Search Google Scholar
  • Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3, 772–775 (2004)

    Park BH , 'The PIK3CA gene is mutated with high frequency in human breast cancers ' (2004 ) 3 Cancer Biol Ther : 772 -775.

    • Search Google Scholar
  • Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11, 2875–2878 (2005)

    Boyd J , 'Frequent mutation of the PIK3CA gene in ovarian and breast cancers ' (2005 ) 11 Clin Cancer Res : 2875 -2878.

    • Search Google Scholar
  • Samuels Y, Diaz L a., Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005)

    Velculescu VE , 'Mutant PIK3CA promotes cell growth and invasion of human cancer cells ' (2005 ) 7 Cancer Cell : 561 -573.

    • Search Google Scholar
  • Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg Å, Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65, 2554–2559 (2005)

    Parsons R , 'PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma ' (2005 ) 65 Cancer Res : 2554 -2559.

    • Search Google Scholar
  • Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102, 802–807 (2005)

    Vogt PK , 'Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic ' (2005 ) 102 Proc Natl Acad Sci U S A : 802 -807.

    • Search Google Scholar
  • Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510 (2008)

    Cantley LC , 'PI3K pathway alterations in cancer: variations on a theme ' (2008 ) 27 Oncogene : 5497 -5510.

    • Search Google Scholar
  • National Center for Biotechnology Information (2014): db SNP (Short Genetic Variations). [Online]. Available: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7640662. [Accessed: July 29, 2014]

    '', in db SNP (Short Genetic Variations) , (2014 ) -.

  • Hildebrandt MAT, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X: Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27, 857–871 (2009)

    Wu X , 'Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy ' (2009 ) 27 J Clin Oncol : 857 -871.

    • Search Google Scholar
  • Wu X, Gu J, Wu T-T, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24, 3789–3798 (2006)

    Ajani JA , 'Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer ' (2006 ) 24 J Clin Oncol : 3789 -3798.

    • Search Google Scholar
  • Sambrook J, Russell DW: Purification of nucleic acids by extraction with phenol:chloroform. Cold Spring Harb Protoc [Online]. Available: http://cshprotocols.cshlp.org/content/2006/1/pdb.prot4455.long [Accessed: January 19, 2014]

    Russell DW , '', in Cold Spring Harb Protoc [Online] , (2014 ) -.

  • Davis MW, Hammarlund M: Single-nucleotide polymorphism mapping. In Methods in molecular biology (Clifton, N.J.). Humana Press, USA, Volume 351, 75–92 (2006)

    Hammarlund M , '', in In Methods in molecular biology , (2006 ) -.

  • International HapMap Consortium: A haplotype map of the human genome. Nature 437, 1299–1320 (2005)

    'A haplotype map of the human genome ' (2005 ) 437 Nature : 1299 -1320.

  • Hoban S, Gaggiotti O, Bertorelle G: Sample Planning Optimization Tool for conservation and population Genetics (SPOTG): A software for choosing the appropriate number of markers and samples. Methods Ecol Evol 4, 299–303 (2013)

    Bertorelle G , 'Sample Planning Optimization Tool for conservation and population Genetics (SPOTG): A software for choosing the appropriate number of markers and samples ' (2013 ) 4 Methods Ecol Evol : 299 -303.

    • Search Google Scholar
  • Owzar K, Li Z, Cox N, Yi C, Jung S: Power and sample size calculations for SNP association studies with censored time to event outcomes. Genet Epidemiol 36, 1–7 (2012)

    Jung S , 'Power and sample size calculations for SNP association studies with censored time to event outcomes ' (2012 ) 36 Genet Epidemiol : 1 -7.

    • Search Google Scholar
  • Spencer CCA, Su Z, Donnelly P, Marchini J: Designing genomewide association studies: Sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 5, e1000477 (2009)

    Marchini J , 'Designing genomewide association studies: Sample size, power, imputation, and the choice of genotyping chip ' (2009 ) 5 PLoS Genet : e1000477 -.

    • Search Google Scholar
  • Daniel WW, Cross CL: Biostatistics: a foundation for analysis in the health sciences, 10th ed. John Wiley & Sons, USA, pp. 161–279 (2013)

    Cross CL , '', in Biostatistics: a foundation for analysis in the health sciences , (2013 ) -.

  • Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 7678–7681 (2004)

    Phillips WA , 'Mutation of the PIK3CA gene in ovarian and breast cancer ' (2004 ) 64 Cancer Res : 7678 -7681.

    • Search Google Scholar
  • Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, Wolp-Diniz R, Richon C, Campone M, Bachelot T, Dalenc F, Dessen P, Lacroix L, Lazar V, Soria JC, Delaloge S, Andre F: Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer 48, 2293–2299 (2012)

    Andre F , 'Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer ' (2012 ) 48 Eur J Cancer : 2293 -2299.

    • Search Google Scholar
  • Jelovac D, Beaver J, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, Vandenberg D, Kessler J, Jeter S, Park BH, Wolff AC: A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Hum Pathol 45, 880–883 (2014)

    Wolff AC , 'A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers ' (2014 ) 45 Hum Pathol : 880 -883.

    • Search Google Scholar
  • Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Høgdall E, Di-Cioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Høgdall C, Blaakaer J, Easton DF, Ponder BAJ, Jacobs IJ, Menon U, Whittemore AS, Krüger-Kjaer S, Pearce CL, Pharoah PDP, Gayther SA: Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 100, 993–1001 (2009)

    Gayther SA , 'Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer ' (2009 ) 100 Br J Cancer : 993 -1001.

    • Search Google Scholar
  • Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, Van De Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68, 6084–6091 (2008)

    Hennessy BT , 'An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer ' (2008 ) 68 Cancer Res : 6084 -6091.

    • Search Google Scholar
  • Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt ANJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107, 10208–10213 (2010)

    Sotiriou C , 'PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer ' (2010 ) 107 Proc Natl Acad Sci U S A : 10208 -10213.

    • Search Google Scholar
  • Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML: Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol 43, 2207–2212 (2012)

    Troxell ML , 'Mucinous breast carcinomas lack PIK3CA and AKT1 mutations ' (2012 ) 43 Hum Pathol : 2207 -2212.

    • Search Google Scholar
  • Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A 110, 14372–14377 (2013)

    Arteaga CL , 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies ' (2013 ) 110 Proc Natl Acad Sci U S A : 14372 -14377.

    • Search Google Scholar
  • Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A, Schewe C, Loibl S, Dietel M, Denkert C: Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mol Morphol 22, 50–56 (2014)

    Denkert C , 'Analysis of PIK3CA mutations in breast cancer subtypes ' (2014 ) 22 Appl Immunohistochem Mol Morphol : 50 -56.

    • Search Google Scholar
  • Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK V, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004)

    Velculescu VE , 'High frequency of mutations of the PIK3CA gene in human cancers ' (2004 ) 304 Science : 554 -.

    • Search Google Scholar
  • de Mello RA, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P, Hespanhol V, Reis RM: The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 loci on the risk and prognosis of Portuguese patients with non-small cell lung cancer. PLoS One 8, e72373 (2013)

    Reis RM , 'The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 loci on the risk and prognosis of Portuguese patients with non-small cell lung cancer ' (2013 ) 8 PLoS One : e72373 -.

    • Search Google Scholar
  • Zhang Y, Liu M, Yang H, Wang J, Liu H, Li X, Li J, Xu J: PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. Neoplasma 61, 461–467 (2014)

    Xu J , 'PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer ' (2014 ) 61 Neoplasma : 461 -467.

    • Search Google Scholar
  • dbSNP Short Genetic Variation Reference SNP (refSNP) Cluster Report: rs7640662, The National Center for Biotechnology Information (NCBI). [Online]. Available: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7640662

  • Slattery ML, Lundgreen A, Mullany LE, Penney RB, Wolff RK: Influence of CHIEF pathway genes on gene expression: A pathway approach to functionality. Int J Mol Epidemiol Genet 5, 100–111 (2014)

    Wolff RK , 'Influence of CHIEF pathway genes on gene expression: A pathway approach to functionality ' (2014 ) 5 Int J Mol Epidemiol Genet : 100 -111.

    • Search Google Scholar
  • Hou W, Liu J, Chen P, Wang H, Ye B-C, Qiang F: Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett 8, 1249–1254 (2014)

    Qiang F , 'Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma ' (2014 ) 8 Oncol Lett : 1249 -1254.

    • Search Google Scholar

2019  
Scimago
H-index
11
Scimago
Journal Rank
0,220
Scimago
Quartile Score
Medicine (miscellaneous) Q3
Scopus
Cite Score
155/133=1,2
Scopus
Cite Score Rank
General Medicine 199/529 (Q2)
Scopus
SNIP
0,343
Scopus
Cites
206
Scopus
Documents
23

 

Interventional Medicine and Applied Science
Language English
Size  
Year of
Foundation
2009
Publication
Programme
changed title
Volumes
per Year
 
Issues
per Year
 
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2061-1617 (Print)
ISSN 2061-5094 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2021 0 0 0
Mar 2021 0 1 1
Apr 2021 0 2 2
May 2021 0 6 10
Jun 2021 0 4 0
Jul 2021 0 0 0
Aug 2021 0 0 0